Previous 10 | Next 10 |
Shares of Aerie Pharmaceuticals (NASDAQ: AERI) jumped more than 14% after the company reported fourth-quarter and full-year 2019 operating results. The commercial-stage pharmaceutical company handily beat expectations for product revenue in the final three months of last year. The business ...
DPW Holdings (NYSEMKT: DPW ) +38% after defense unit gets $1.4M follow-on order . More news on: DPW Holdings, Inc., California Resources Corporation, Baudax Bio, Inc., Stocks on the move, , Read more ...
Aerie Pharmaceuticals (NASDAQ: AERI ) Q4 results : More news on: Aerie Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Aerie Pharmaceuticals, Inc. (AERI) Q4 2019 Earnings Conference Call February 20, 2020 5:00 PM ET Company Participants Ami Bavishi - Director of Investor Relations Vicente Anido - Chief Executive Officer Thomas Mitro - President and Chief Operating Officer Richard Rubino - Chief...
Aerie Pharmaceuticals (NASDAQ: AERI ): Q4 Non-GAAP EPS of -$0.96 misses by $0.19 ; GAAP EPS of -$1.21 misses by $0.24 . Revenue of $24.66M (+70.5% Y/Y) beats by $5.22M . Shares +6.4% . Press Release More news on: Aerie Pharmaceuticals, Inc., Earnings news and commentary, Stocks...
Conference Call and Webcast Today, February 20 th , at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glau...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announc...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced tod...
Aerie Pharmaceuticals (NASDAQ: AERI) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are including IQVIA scripts for Rhopressa and Rocklatan below for the week ended 1/31/2020. Please note that these numbers were affecte...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announc...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...